Premium
Hepatic ablation for neuroendocrine tumor metastases
Author(s) -
Maithel Shishir K.,
Fong Yuman
Publication year - 2009
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21196
Subject(s) - medicine , ablation , neuroendocrine tumors , radiofrequency ablation , disease , surgery , embolization , ablation therapy , neuroendocrine carcinoma , radiology , oncology , cancer , carcinoma , prostate cancer
Abstract The indolent nature of neuroendocrine tumors and their proclivity to be hormonally active warrant aggressive treatment for advanced stage disease with hepatic metastases. Cytoreduction has been associated with improved symptom control as well as prolonged survival compared with those treated with medical therapy. The primary modalities of cytoreduction employed are resection, ablation, and embolization. In particular, radiofrequency ablation has been utilized with good results and minimal morbidity for treating patients with advanced neuroendocrine disease. J. Surg. Oncol. 2009;100:635–638. © 2009 Wiley‐Liss, Inc.